- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04799847
Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine
A Multicenter, Non-randomized, Uncontrolled, Open-label Phase I/II Study to Observe the Safety and Preliminary Efficacy of Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine
Study Overview
Detailed Description
This is a multicenter, non-randomized, uncontrolled, open-label phase I/II study to observe the safety and preliminary efficiency of catumaxomab in patients (hereinafter referred to as participants) with non-muscle-invasive bladder cancer (NMIBC) who have failed or are intolerant to Bacillus Calmette-Guerin (BCG) vaccine.
This study is conducted in 3 phases sequentially: dose escalation phase, dose expansion phase and dose extension phase. In the dose escalation phase, the preliminary safety and pharmacokinetic profile of catumaxomab for 4 cycles of instillation in 20ug group participants and 2cycles of instillation in 100ug group participants are explored. Data will be collected after completing DLT observation in all cohorts, but it is not required to lock database. DSMB will review the data of each dose cohort and decide whether to open the enrollment for the next cohort. DSMB will recommend the dose at dose expansion phase according to the relevant data after the completion of DLT observation and the first efficiency assessment.
In the dose expansion phase, 24 participants will receive the catumaxomab treatment at dosing scheme recommended by the DSMB. DLT events occurred within 28 days after the initial instillation will be investigated. After th DLT observation period, DSMB will evaluate the data from both dose escalation and dose expansion phase and decide whether to initiate the dose extension phase; protocol amendment might be developed.
In the dose extension phase, the elgible participants are enrolled and allocated into three arms according to the type of BCG treatment failure: refractory, relapse, and intolerance. A maximum 125 participants are enrolled in the 3 arms, with at least 30 participants allocated to each.
The participants will have chest and abdominal CT and pelvic MRI scan at baseline to determine the area of lesion and to rule out possible extra-bladder lesions. From the initial instillation, cystoscopy, bladder biopsy, urinary cytology, and pelvic MRI scan are performed every 12 weeks (±7 days); chest and abdominal CT scans are performed every 24 weeks (±7 days)1 until recurrence, progression, consent withdrawal, or 96 weeks (±7 days) from the initial instillation, whichever occurs firstly. Participants who discontinue study treatment early due to any reasons other than disease progression will continue to have the tumor response assessment as planned until the participant has disease progression, withdrawal of consent, loss of follow-up, death, 96 weeks (± 7 days) after the initial instillation or until the end of the study, whichever occurs firstly.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Beijing, China
- Recruiting
- Peking University Third Hospital
-
Contact:
- Lulin Ma
- Phone Number: 13701010872
- Email: malulin@medmail.com.cn
-
Guangzhou, China
- Recruiting
- Sun Yat-sen University Cancer Center
-
Contact:
- Zhuowei Liu
- Phone Number: 13610138571
- Email: liuzhw@sysucc.org.cn
-
Principal Investigator:
- Zhuowei Liu
-
Tianjin, China
- Recruiting
- The Second Hospital of Tianjin Medical University
-
Principal Investigator:
- Hailong Hu
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Recruiting
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University
-
Contact:
- Jian Huang
- Phone Number: 13600054833
- Email: hjgcp2017@163.com
-
Guangzhou, Guangdong, China, 510080
- Recruiting
- The First Affiliated Hospital,Sun Yat-sen University
-
Contact:
- Lingwu Chen
- Phone Number: 13302283888
- Email: chenlingwu@hotmail.com
-
Principal Investigator:
- Lingwu Chen
-
Principal Investigator:
- Xugang Dong
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed and dated informed consent forms have been provided.
- Willing to be complaint with the study procedures during the study.
- Male or female, age ≥ 18 years old when signing informed consents.
- Histologically or cytologically diagnosed as NMIBC, i.e., bladder cancer in the following pTNM status: pTis, pTa, pT1.
- Have received the standard therapy recommended in the current NMIBC clinical guidelines, including intravesical BCG instillation, and diagnosed as BCG failure or intolerance.
- Participants had completed TURBT or cystoscopy as required by guidelines prior to enrollment, and no significant tumours were seen in the surgical field Residual lesions
- Recovered from any toxicity due to previous treatment (Grade 0-1 according to NCI-CTCAE v 5.0).
- Estimated life span is ≥ 6 months.
- Eastern Oncology Cooperative Group (ECOG) performance status 0-1.
The laboratory test values during the screening period are in accordance with the following table:
- ANC(absolute neutrophil count)>=1.5x10^9/L
- Hemoglobin>=80 g/L
- Platelet>=100x10^9/L
- Lymphocyte percentage>=20%
- Serum Bilirubin <=1.25
- ULN(or 2.5 ULN if there is Gilbert)
- AST and ALT <=2.5 ULN without liver metastasis(or<=5 ULN if liver metastasis)
- Serum creatinine <=2.0 mg/dL or
- Calculated creatinine clearance>=30 mL/min.
- For women of childbearing potential: use an efficient method for contraception at least 1 month prior to screening and agree to use this method for contraception during the study period and 30 days after the last intravesical instillation.;
- For men with fertility potential: use condoms or other methods to ensure effective contraception for sexual partners from screening to 30 days after the last intravesical instillation.
Exclusion Criteria:
- Known or suspected of being allergic to catumaxomab or similar antibodies.
- Besides the TURBT + immediate postoperative infusion chemotherapy for this NMIBC recurrence, participants received other anti-tumor treatments, including other anti-tumor investigational drugs, chemotherapy, immunotherapy, biological agents, hormone therapy, radiation therapy (excluding local radiation therapy for pain relief), etc., the interval between the last instillation and the first intravesical instillation is ≤ 21 days.
- Tumor metastases outside the bladder confirmed in imaging examination.
- With other primary malignant tumors diagnosed before the signing of ICF, excluding squamous cell carcinoma in situ of skin or cervical carcinoma in situ without recurrence within 5 years after resection.
The following diseases have not been resolved to CTCAE grade 0-1 in 3 days prior to the first instillation:
- Uncontrolled acute and chronic infections such as pneumonia, biliary infection, hepatitis B virus infection and hepatitis C virus infection, etc.
- Dyspnea.
- Acute /chronic renal injury.
- Nephrotic syndrome.
- Bladder perforation.
- Urinary tract obstruction(except benign prostatic hypertrophy).
- NYHA Class 3 or 4.
- Related symptoms and signs of cardiovascular diseases have not been resolved to CTCAE grade 0-1: including myocardial infarction, congestive heart failure, and arrhythmia.
- Known cerebrovascular accidents have not been resolved to CTCAE grade 0-1.
- History of autoimmune diseases (eg, inflammatory bowel disease, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, autologous hemolytic anemia, rheumatoid arthritis, etc.).
Patients with known HIV serology positive, hepatitis C infection and/or hepatitis B (Except the patients with positive HepBsAg or core antibody are responding to anti-HBV treatment, they are allowed to participate in the study.
Notes: HepBsAg-negative patients at screening, or patients are undergoing treatment with interferon-2a [IFN] or peginterferon-2a [Peg-IFN] and hepatitis B virus [HBV] DNA < 2000 international units [IU], or partients who are receiving nucleoside [acid] analogues at screening and HBV DNA below the lower limit of normal [LLN] are eligible to participate in the study.
- Pregnancy or breastfeeding during study treatment and follow-up period.
- Patients with confirmed past history of neurological or psychotic disorders, including epilepsy or dementia.
- Other serious systemic conditions that may limit the participation in this study (e.g. uncontrolled diabetes, cardiovascular and cerebrovascular disease, severe gastrointestinal disease, and renal disease, etc.).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SEQUENTIAL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Catumaxomab
In the dose escalation phase, 2 dose levels of catumaxomab will be explored.
|
This study is conducted in 3 phases sequentially: dose escalation phase, dose expansion phase and dose extension phase.
In the dose escalation phase, the preliminary safety and pharmacokinetic profile of catumaxomab by instillation, at 2 dose levels(20ug group and 100ug group), in NMIBC patients are investigated.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose escalation phase and dose expansion phase only: DLT incidence.
Time Frame: 28 days
|
Dose Limited Toxicity
|
28 days
|
1-year recurrence rate since the initial instillation
Time Frame: 1 year
|
1-year recurrence rate since the initial instillation
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recurrence rate at 3 months / 6 months / 2 years.
Time Frame: Up to 2 years
|
Recurrence rate at 3 months / 6 months / 2 year
|
Up to 2 years
|
PFS
Time Frame: 2 years
|
Relapse-free survival
|
2 years
|
2-year progression rate to MIBC.
Time Frame: 2 years
|
2-year progression rate to MIBC.
|
2 years
|
The incidence and severity of treatment-emergent adverse events (TEAEs) and Serious adverse event(SAE)
Time Frame: 2 years
|
The incidence and severity of treatment-emergent adverse events (TEAEs) and Serious adverse event(SAE) during intravesical instillation with catumaxomab are observed according to the National Cancer Institute Common Terminology Standard for Adverse Events (NCI-CTCAE) v5.0.
|
2 years
|
ADA
Time Frame: 2 years
|
the incidence of anti-drug antibodies (ADA) to catumaxomab by intravesical instillation in serum.
|
2 years
|
Pharmacokinetic parameters-Cmax
Time Frame: 2 years
|
Pharmacokinetic parameters Cmax of bladder perfusion of Catumaxomab in plasma and urine
|
2 years
|
Pharmacokinetic parameters-Cmin
Time Frame: 2 years
|
Pharmacokinetic parameters Cmin of bladder perfusion of Catumaxomab in plasma and urine
|
2 years
|
Pharmacokinetic parameters-AUC
Time Frame: 2 years
|
Pharmacokinetic parameters-AUC of bladder perfusion of Catumaxomab in plasma and urine
|
2 years
|
Pharmacokinetic parameters-t1/2
Time Frame: 2 years
|
Pharmacokinetic parameters-t1/2 of bladder perfusion of Catumaxomab in plasma and urine
|
2 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LP0190512
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bladder Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage III Bladder Cancer | No Evidence of Disease | Stage II Bladder Cancer | Stage IVA Bladder Cancer | Stage IVB Bladder CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteCompletedMuscle-Invasive Bladder Carcinoma | Bladder Cancer Stage II | Bladder Cancer Stage III | Bladder Cancer Stage IVUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnRecurrent Bladder Cancer | Urinary Complications | Stage 0 Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder Cancer
-
National Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
Fox Chase Cancer CenterTerminatedStage III Bladder Cancer | Distal Urethral Cancer | Proximal Urethral Cancer | Squamous Cell Carcinoma of the Bladder | Urethral Cancer Associated With Invasive Bladder Cancer | Stage II Bladder CancerUnited States
-
National Cancer Institute (NCI)TerminatedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Bladder Urothelial Carcinoma | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Stage II Bladder CancerUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Bristol-Myers SquibbRecruitingUrinary Bladder Cancer | Invasive Bladder CancerNetherlands
-
Taris Biomedical LLCBristol-Myers SquibbTerminatedBladder Cancer TNM Staging Primary Tumor (T) T2 | Bladder Cancer TNM Staging Primary Tumor (T) T2A | Bladder Cancer TNM Staging Primary Tumor (T) T2B | Bladder Cancer TNM Staging Primary Tumor (T) T3 | Bladder Cancer TNM Staging Primary Tumor (T) T3A | Bladder Cancer TNM Staging Primary Tumor... and other conditionsUnited States
-
Baylor College of MedicinePfizerTerminatedBladder Cancer | Invasive Bladder Cancer | Metastatic Bladder CancerUnited States
Clinical Trials on Catumaxomab
-
Neovii BiotechFresenius Biotech North AmericaCompletedMalignant AscitesUnited States
-
Neovii BiotechCompletedMalignant Ascites Due to Epithelial CarcinomaGermany
-
Neovii BiotechCompletedGastric Cancer | Gastric AdenocarcinomaGermany
-
Neovii BiotechFresenius Biotech North AmericaCompletedOvarian CancerUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisTerminatedPatients With Gastric Peritoneal CarcinomatosisFrance
-
Neovii BiotechCompletedMalignant Ascites | EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast)
-
Neovii BiotechTerminatedEpithelial Cancer PatientsAustria, Denmark, Spain
-
Neovii BiotechCompletedGastric Cancer | Gastric AdenocarcinomaAustria, Spain, United Kingdom, Germany
-
Lindis Biotech GmbHRecruitingUrinary Bladder NeoplasmsGermany
-
Grupo Español de Investigación en Cáncer de OvarioNeovii BiotechCompleted